Antifungal Resistance, Susceptibility Testing and Treatment of Recalcitrant Dermatophytosis Caused by Trichophyton indotineae: A North American Perspective on Management-Reference-Cited by-同舟云学术

Antifungal Resistance, Susceptibility Testing and Treatment of Recalcitrant Dermatophytosis Caused by Trichophyton indotineae: A North American Perspective on Management

Published:2023-08-08 Issue:6 Volume:24 Page:927-938
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Gupta Aditya K.^ORCID,Polla Ravi Shruthi^ORCID,Wang Tong^ORCID,Cooper Elizabeth A.^ORCID,Lincoln Sara A.,Foreman Hui-Chen,Bakotic Wayne L.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-023-00811-6.pdf

Reference70 articles.

1. Institute of Health Metrics and Evaluation. Fungal skin diseases—level 3 cause [Internet]. Global Burden of Disease. 2019. https://www.healthdata.org/results/gbd_summaries/2019/fungal-skin-diseases-level-3-cause.

2. Urban K, Chu S, Scheufele C, Giesey RL, Mehrmal S, Uppal P, et al. The global, regional, and national burden of fungal skin diseases in 195 countries and territories: a cross-sectional analysis from the Global Burden of Disease Study 2017. JAAD Int. 2021;2:22–7.

3. Benedict K, Tsay SV, Bartoces MG, Vallabhaneni S, Jackson BR, Hicks LA. Outpatient antifungal prescribing patterns in the United States, 2018. Antimicrobial stewardship & healthcare epidemiology: ASHE [Internet]. 2022 [cited 2023 Jun 19];1. https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/35910521/.

4. Benedict K, Wu K, Gold JAW. Healthcare provider testing practices for tinea and familiarity with antifungal-drug-resistant tinea—United States, 2022. J Fungi [Internet]. 2022 [cited 2023 Jun 19];8. Available from: /pmc/articles/PMC9410453/.

5. Chowdhary A, Singh A, Kaur A, Khurana A. The emergence and worldwide spread of the species Trichophyton indotineae causing difficult-to-treat dermatophytosis: a new challenge in the management of dermatophytosis. PLoS Pathog [Internet]. 2022 [cited 2023 Mar 5];18:e1010795. https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/36173977/.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifungal resistance in dermatophytes – review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections;Expert Review of Anti-infective Therapy;2024-08-18

2. Trichophyton indotineae, an Emerging Drug-Resistant Dermatophyte: A Review of the Treatment Options;Journal of Clinical Medicine;2024-06-18

3. Safety and efficacy of new generation azole antifungals in the management of recalcitrant superficial fungal infections and onychomycosis;Expert Review of Anti-infective Therapy;2024-06-02

4. Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management;Mycopathologia;2024-05-11

5. An update on antifungal resistance in dermatophytosis;Expert Opinion on Pharmacotherapy;2024-03-23